NCT02087059 - A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions

Primary Myelofibrosis (MF)

Interventions

DRUG

Ruxolitinib

Trial Locations (29)

467-8602

Novartis Investigative Site, Nagoya

010-8543

Novartis Investigative Site, Akita

790-8524

Novartis Investigative Site, Matsuyama

791-0295

Novartis Investigative Site, Tōon

812-8582

Novartis Investigative Site, Fukuoka

830-0011

Novartis Investigative Site, Kurume

501-1194

Novartis Investigative Site, Gifu

371-8511

Novartis Investigative Site, Maebashi

060-8543

Novartis Investigative Site, Sapporo

060-8648

Novartis Investigative Site, Sapporo

650-0017

Novartis Investigative Site, Kobe

650-0047

Novartis Investigative Site, Kobe

860-8556

Novartis Investigative Site, Kumamoto

606-8507

Novartis Investigative Site, Kyoto

514-8507

Novartis Investigative Site, Tsu

980-8574

Novartis Investigative Site, Sendai

889-1692

Novartis Investigative Site, Miyazaki

700-8558

Novartis Investigative Site, Okayama

573-1191

Novartis Investigative Site, Hirakata

589-8511

Novartis Investigative Site, Sayama

565-0871

Novartis Investigative Site, Suita

329-0498

Novartis Investigative Site, Shimotsuke

113-8431

Novartis Investigative Site, Bunkyo-ku

113-8519

Novartis Investigative Site, Bunkyo-ku

113-8603

Novartis Investigative Site, Bunkyo-ku

113-8677

Novartis Investigative Site, Bunkyo-ku

160-0023

Novartis Investigative Site, Shinjuku-ku

162-8666

Novartis Investigative Site, Shinjuku-ku

409-3898

Novartis Investigative Site, Chūō